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Abstract Affinity and dose of T cell receptor (TCR) interaction with antigens govern the
magnitude of CD4+ T cell responses, but questions remain regarding the quantitative translation of
TCR engagement into downstream signals. We find that while the response of mouse CD4+ T cells
to antigenic stimulation is bimodal, activated cells exhibit analog responses proportional to signal
strength. Gene expression output reflects TCR signal strength, providing a signature of T cell
activation. Expression changes rely on a pre-established enhancer landscape and quantitative
acetylation at AP-1 binding sites. Finally, we show that graded expression of activation genes
depends on ERK pathway activation, suggesting that an ERK-AP-1 axis plays an important role in
translating TCR signal strength into proportional activation of enhancers and genes essential for T
cell function.
DOI: 10.7554/eLife.10134.001
Introduction
The question of how the T cell receptors (TCRs) of CD4+ T cells respond to ligands of differing affini-
ties and concentrations with such remarkable specificity is of great interest to the study of immunity.
The TCR binds to antigen presented by the molecules encoded by the Major Histocompatibility
Complex (MHC) such that strength of the TCR signal in response to a particular peptide-MHC com-
plex (pMHC) is dependent on all three components– the antigenic peptide, the MHC, and the TCR
itself (Heber-Katz et al., 1982). Variations in signal efficiency are thus caused by the generated TCR
sequence (Hedrick et al., 1984; Jerne, 1971), genetic differences in MHC (Heber-Katz et al., 1982;
Hedrick et al., 1982), and the peptide being presented (Solinger et al., 1979). Even small differen-
ces in the number or affinity of these pMHC-TCR interactions are read by the TCR and have impor-
tant consequences for the nature and extent CD4+ T cell activation; high-affinity interactions lead to
inflammatory responses at a lower concentration of antigen, increased Interleukin 2 (IL2) and IFNg
production, and increased proliferation (Heber-Katz et al., 1982; Hedrick et al., 1982;
Solinger et al., 1979; Alexander, 1993; Rogers and Peptide dose, 1999; Rogers et al., 1998;
Sloan-Lancaster et al., 1993; Tubo et al., 2013), whereas lower affinity interactions can lead to
incomplete phosphorylation of downstream signaling complexes (Kersh et al., 1998b; Sloan-
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Lancaster et al., 1994), anergy (Sloan-Lancaster et al., 1993, 1994), or TCR antagonism (Alexan-
der, 1993; Kersh et al., 1998b). The precise result of low-affinity engagement varies with experi-
mental conditions, but in each case, a cellular phenotype distinct from high-affinity engagement is
produced.
There exists a well-characterized model system for studying the effects of ligand affinity on CD4+
T cell activation: the AND mouse is a strain with a transgenic CD4+ T cell TCR (Kaye et al., 1989).
This TCR recognizes pigeon cytochrome c (PCC) along with synthetic and species-variant cyto-
chrome c oligopeptides (Solinger et al., 1979; Rogers and Peptide dose, 1999; Rogers et al.,
1998). Notably, though many of the peptides differ from PCC by a single amino acid, the effects of
TCR recognition of the peptides vary greatly. Kinetic parameters and cytokine output of the interac-
tion with many cytochrome c peptides and their analogues have been described (Rogers and Pep-
tide dose, 1999; Rogers et al., 1998). Differences in microcluster formation at the membrane have
likewise been described (Varma et al., 2013).
These variable responses to ligands of differing affinity are especially interesting in the context of
the digital TCR response. TCR responses have been characterized as digital (Coward et al., 2010)—
that is, signaling downstream of the TCR is either all-on or all-off, such that a given T cell must either
be committed to a full response or to no response. Previous work has established this switch-like
behavior as observable in terms of extracellular markers such as CD69 (Das et al., 2009;
Daniels et al., 2006), ERK pathway component localization (Das et al., 2009; Daniels et al., 2006;
Prasad et al., 2009), NF-kB activation (Kingeter et al., 2010), NFAT localization (Marangoni et al.,
2013; Podtschaske et al., 2007), cell-cycle entry (Au-Yeung et al., 2014), and cytokine production
(Podtschaske et al., 2007; Huang et al., 2013). As a result, differences in the magnitude of
responses to ligands of varying affinity would be attributed to greater frequencies of T cells respond-
ing at the population level, rather than per-cell variability (Au-Yeung et al., 2014; Huang et al.,
2013; Zikherman and Au-Yeung, 2015; Butler et al., 2013). Still, some aspects of the TCR
response have been described as analog, or varying in proportion to the strength of signaling: CD3z
chain phosphorylation (Kersh et al., 1998a; Sloan-Lancaster et al., 1994; Daniels et al., 2006;
Kersh et al., 1999; Kersh et al., 1998a); Zap70 activation (Daniels et al., 2006; Prasad et al.,
2009); intracellular calcium concentrations (Irvine et al., 2002); expression of the transcription factor
eLife digest T helper cells recognize and respond to bacteria, viruses and other invading
microbes and thus play a central role in the adaptive immune system. These cells have a receptor on
their surface that binds to fragments of proteins – known as oligopeptides – from the microbes that
have been digested and presented on the surfaces of other immune cells. Once active, T helper cells
multiply, grow and release signals that regulate genes in other cells to promote immune responses.
Previous studies suggest that a T helper cell’s response is binary – that is, either on or off. However,
this does not explain how the strength of the T cell response to infection can vary.
Allison et al. used a technique called high-throughput sequencing to examine the activity of
genes in T helper cells from mice that had been genetically engineered to only produce one type of
T cell receptor. For the experiments, the T cells were exposed to various concentrations of different
peptides known to bind either well or poorly to the receptor. Allison et al. found that, once
activated, the response of an individual T cell was not binary, but instead was related to the strength
of the signal it received through its receptor.
Further experiments showed that although a subset of the genes activated in T helper cells do
respond in a binary fashion, the activities of many other genes involved in immune responses and
cell metabolism were related to the strength of the signal from the receptor. This “analog” gene
activation depends on the level of activity of the MAP kinase signaling pathway. Together, Allison
et al.’s findings help us to understand how T cells are able to fine-tune immune responses to
invading microbes. The next challenge will be to investigate the mechanisms underlying binary and
analog gene activity in T cells.
DOI: 10.7554/eLife.10134.002
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IRF4 (Man et al., 2013; Nayar, 2014); and cell division time (Marchingo, 2014). It is unclear how
these analog components of the TCR response fit in to a digital model.
Both the ability of the TCR to discriminate with high resolution between ligands and the digital
nature of TCR signaling have been extensively studied at the level of signaling. Downstream of the
TCR, a number of signaling pathways govern the molecular response to engagement, allowing T
cells to grow, divide, and acquire immune effector functions consistent with the inciting stimulus
(Murphy and Blenis, 2006; O’Sullivan and Immunology, 2015; Proud, 2007; Santamaria and
Ortega, 2006; Wang and Green, 2012). AKT and PKCq interact at the cell membrane and jointly
serve to induce nuclear translocation of the pro-inflammatory transcription factor NF-kB, which in
turn is able to activate target genes (Huang and Wange, 2004). In particular, AP-1, which comprises
homo- or heterodimers assembled from proteins of the Fos, Jun, and ATF transcription factor fami-
lies (Murphy et al., 2013), requires both TCR and co-stimulatory signaling (Rinco´n and Flavell,
1994), and it is usually activated by the Ras/Raf/Mek/Erk pathway (Murphy and Blenis, 2006;
Schade and Cutting edge, 2004). At least four feedback loops have been identified in thymocytes
and peripheral T cells downstream of the TCR (Coward et al., 2010; Feinerman et al., 2008). Col-
lectively, these feedback loops serve to enforce a digital response by either dampening sub-thresh-
old signaling or amplifying above-threshold signaling, resulting in T cell responses that are all-off or
all-on, respectively.
Despite these insights into the signaling pathways downstream of TCR activation, there is little
known about the transcriptional programs that determine the distinct phenotypes resulting from
high- versus low-affinity stimulation. In this study, we address the question of affinity at the level of
the chromatin. We take advantage of the PCC system to assess the effects of varying the dose and
affinity of peptide presentation to CD4+ T cells on enhancer formation and gene expression, giving
us a genome-wide picture of how TCR signaling is able to achieve such highly specific responses
despite its apparent digital signaling pattern. We find first that the digital/analog dichotomy is too
simple, and instead CD4+ T cells respond to ligands of varying dose and affinity by modulating both
the frequency of responding cells and the level of activation of responding cells at a single cell level.
In other words, activation markers are analog with respect to the strength of TCR signaling when
comparing across doses and affinities, but for any single dose and affinity, the overall signaling pat-
tern is digital for the population of cells. We next show that at the population level, the combined
effects of analog precision and increasing frequency of responder cells produce gene expression
patterns that directly reflect the strength of TCR signaling for a set of activation signature genes.
These gene expression patterns can be used to assess CD4+ T cell activation status, and we develop
a tool for ranking arbitrary CD4+ T cell populations by activation score. Underlying these gene
expression patterns, we find that the enhancer landscape is largely pre-existing, such that TCR
engagement results in activation of primed enhancers rather than through selection of new
enhancers. Finally, we show that the graded activation score and the expression of activation signa-
ture genes are dependent on the amount of phosphorylated ERK activity downstream of the TCR.
Together, these results suggest that the degree of ERK activation translates the analog TCR signal
resulting from varying the dose and affinity of TCR engagement into downstream gene expression
programs.
Results
The TCR response is analog: quantitative responses to signal strength
In order to understand the effects of the digital TCR response on the transcriptional landscapes of
CD4+ T cells, we first sought to characterize the ’on-state’ of the TCR response. CD4+ T cells and
CD11c+ antigen presenting cells (APCs) were isolated from AND transgenic mice (Figure 1—figure
supplement 1A,B) and co-cultured for 24 hr with one of a panel of previously described
(Rogers and Peptide dose, 1999; Rogers et al., 1998) peptides at several different doses. Cell acti-
vation was then measured at a single cell level using flow cytometry. As expected, for each given
peptide and dose, CD4+ T cells followed a digital pattern, appearing either all-on or all-off accord-
ing to extracellular activation markers such as CD69 (Figure 1A) and CD25 (Figure 1B). Increasing
the peptide dose or affinity significantly increased the percent of activated cells in the population
(Figure 1C,D). However, when we compared across peptides and concentrations, it was clear that
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Figure 1. Both frequency of responding cells and per-cell activation levels increase with increasing signal strength. (A) Purified AND T cells and CD11c
+ APCs were co-cultured in the presence of indicated peptides at the indicated concentrations for 24 hr. Flow cytometry was then used to phenotype
Figure 1 continued on next page
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the activation level of the on-state cells was not ’all on.’ Gating on CD69+ cells, each different pep-
tide and different dose of a peptide achieved a different amount of CD69 per cell (Figure 1E). Gat-
ing on CD25+ cells yields similar results, with varying amounts of CD25 expressed per cell
dependent on both the dose and the affinity of the stimulation (Figure 1F). Thus, while under a
given condition the CD4+ T cells were either on or off as per classical digital signaling, when com-
paring across a panel of conditions, the activation level of the on-state cells is analog with respect to
the strength of the TCR signal.
Gene expression is graded genome-wide
In order to understand the effect of this variability genome-wide, we selected two peptides—the
low-affinity K99A and the high-affinity PCC—and sequenced mRNA from CD4+ T cells exposed to
both a low and a high concentration of each peptide. We compared the gene expression profiles at
24 hr across five conditions (no-peptide; low-dose, low-affinity (10 mM K99A); high-dose, low-affinity
(100 mM K99A); low-dose, high-affinity (0.1 mM PCC); and high-dose, high-affinity (10 mM PCC)), four
out of five of which displayed some degree of activation as measured by extracellular markers such
as CD69 or CD25. We used principal component analysis (PCA) to determine the primary axes of
variation across the approximately 3,000 genes that were expressed above ten reads per kilobase
per million (RPKM) and at least two-fold different between any two conditions. A single principal
component explained more than 99% of the variance in gene expression changes (Figure 2—figure
supplement 1A).
The first principal component ranks the samples according to what would be expected based on
TCR signal strength and extracellular markers such as CD69 and CD25 (Figure 2A). As PC1 captured
the gene expression changes concomitant with increasing activation, we extracted the most positive
10% and most negative 10% of the genes along PC1 to determine which genes were important for
the axis. The 10% of genes contributing the most positive signal to PC1 were increasing in a gener-
ally graded manner with TCR signal strength across the samples, and the 10% of genes contributing
the most negative signal were decreasing (Figure 2B; two-tailed p-values based on permutation
testing of 2.9e-11 and 1.8e-28, respectively).
Collectively, the most indicative 10% of genes for PC1 provide a multidimensional signal for rank-
ing the samples in one dimension according to TCR signal strength and activation state of the CD4+
T cell; we therefore call these genes “activation signature genes.” Looking more closely at the genes
in this group, we see many well-documented immune response genes such as Tbx21 (Tbet), Stat1,
and Tnf (Figure 2C), all of which increase in a graded manner along with TCR signal strength at the
population level. Irf4, previously reported to increase in expression in an analog manner downstream
of the TCR on a per-cell basis (Man et al., 2013; Nayar, 2014), was also among the activation signa-
ture genes, and showed the same graded response pattern at the population level across the condi-
tions (Figure 2D). Gene Ontology analysis yielded several enriched gene categories among the
activation signature, including Myc targets, post transcriptional regulation of gene expression,
MTORC1 signaling and response to cytokine and regulation of translational initiation (Figure 2E)
exemplified by Eif3a (Figure 2—figure supplement 1B). Protein biosynthesis has been previously
shown to be increased upon T cell activation, and here we see that many of the genes involved in
increasing translational activity are themselves up-regulated in a manner that is proportional to the
Figure 1 continued
the CD4+ T cells. The histograms show CD69 expression of CD4+ T cells. The annotated bar indicates the gate used to identify CD69+ CD4 cells in
subsequent figures. (B) Gating on CD4+ cells as in 1A, there is a bimodal distribution of CD25 expression resulting from activating levels of high-affinity
(PCC) or low-affinity (K99A) peptides. The annotated bar indicates the gate used to identify CD25+ cells. (C) The percent of CD4+ cells that are CD69+
(using gate shown in 1A) varies with the peptide presented and concentration of the indicated peptide. (D) The percent of CD4+ cells that are positive
for the activation marker CD25 varies with both peptide and dose. (E) Gating on CD4+ CD69+ cells (as shown in 1A), the geometric mean fluorescence
intensity (MFI) of CD69 per cell in each condition varies. (F) The geometric MFI of CD25, gated on CD4+ CD25+ cells (as shown in 1C), varies with
peptide and dose. (P-values based on Student’s t test; *p<0.05, **p<0.01, ***p<0.001.)
DOI: 10.7554/eLife.10134.003
The following figure supplement is available for figure 1:
Figure supplement 1. CD4+ T cells and APCs were purified from AND mice.
DOI: 10.7554/eLife.10134.004
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Figure 2. RNA-Sequencing reveals graded expression of activation signature genes. (A) Principal component analysis (PCA) of the approximately 3,200
genes that changed between any two samples reveals that the primary axis of variation (PC1, shown along the x-axis) orders the five conditions by
Figure 2 continued on next page
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level of activation across the population (Beretta, 2004; Bjur et al., 2013). Another enriched onto-
logical category was molecular chaperone genes that are responsible for protein folding and unfold-
ing, including six of the Cct family of chaperones (for example, Cct2: Figure 2—figure supplement
1C) and five heat shock family members (for example, Hsph1) that increased with TCR signal
strength.
The graded increase of activation signature genes at the population level corresponded with sin-
gle-cell increases in CD69 and CD25 protein, but it was unclear whether the graded response of pro-
teins associated with activation signature genes was generalizable. In order to determine whether
proteins derived from activation signature genes increased on a per-cell basis in more cases, we
determined the per-cell protein levels of a panel of genes from the activation signature set with flow
cytometry. Not all increases in mRNA levels were reflected at the level of protein (Figure 2—figure
supplement 1D), but for those that were, the increases in mRNA resulted in increases both in the
frequency of cells responding (data not shown) and in protein levels on a per-cell basis. This is exem-
plified by the expression of Tbet (Figure 2F), IRF4 (Figure 2G), CD200 (Figure 2—figure supple-
ment 1E), Ly6a (Figure 2—figure supplement 1F), and Tnsf11 (RANKL; Figure 2—figure
supplement 1G).
Per-cell transcription levels are analog for a subset of genes
To investigate whether graded levels of expression of activation signature genes seen at the RNA
level was a reflection of per-cell activation levels or just the frequency of responder cells we con-
ducted both RNA flow cytometry and RNA-seq for cells sorted by extracellular CD69 expression.
RNA flow cytometry involves the hybridization of fluorescent probes to RNA targets within a cell, fol-
lowed by analysis of per-cell fluorescence via flow cytometry. Thus, observed fluorescence intensity
corresponds directly to single-cell expression levels of mRNAs of interest. Using this technique, we
observed that mRNA expression levels of Irf4 increased across the five conditions on a per-cell basis
in the same manner as seen at the population level and at the protein level (Figure 3—figure sup-
plement 1A). For each population, the mean fluorescence intensities of Irf4 mRNA increased in the
same manner as seen with population-level mRNA expression and single-cell protein levels
(Figure 3A, Figure 3—figure supplement 1B). In contrast, beta actin mRNA as measured by this
technique was constant under each treatment condition (Figure 3—figure supplement 1C,D). Thus,
for some mRNAs, in addition to modulating the frequency of responding cells, peptide dose and
affinity tune the strength of response to TCR signaling on a per-cell basis.
In order to look genome-wide, we conducted RNA-sequencing on CD4+ T cells treated as
before, but sorted by the activation marker CD69, such that we selectively analyzed responder cells.
In this way, we were able to control for the effect of frequency—the observed RNA-seq levels for
Figure 2 continued
increasing TCR signal strength: No Peptide; low-dose, low-affinity (10 mM K99A); high-dose, low-affinity (100 mM K99A); low-dose, high-affinity (0.1 mM
PCC); and high-dose, high-affinity (10 mM PCC). (B) After ordering the ~3200 genes used for PCA by their contribution to PC1, we extracted the top
10%—that is, the ~320 genes contributing most positively to a sample’s PC1 value—and the bottom 10%—that is, the ~320 genes contributing most
negatively to a sample’s PC1 value. Each group displays a clear trend, with the top 10% increasing in expression as signal strength increases, and the
bottom 10% decreasing in expression. Each blue line represents a gene, with reads per kilobase per million (RPKM) normalized from 0 to 1 across the
five conditions. Significance was determined using permutation testing, where the mean difference between genes in the No Peptide sample as
compared to 10 mM PCC was normally distributed over randomly generated groups of genes. This normal distribution was compared to the top 10%
and bottom 10% genes to generate a p-value. (C) Genes in the top 10% of PC1, termed activation signature genes, include many genes previously
identified as important to CD4+ T cell activation, such as Tbx21 (Tbet), Stat1, and Tnf. Reads per kilobase per million (RPKM) for each increases with
increasing signaling strength. (D) Irf4, a transcription factor previously shown to be more highly expressed with increasing TCR affinity, shows graded
expression across the five conditions. (E) Gene Ontology (GO) analysis of activation signature genes shows enrichment for protein biosynthesis and
molecular chaperone genes. P-values shown are Benjamini-Hochberg adjusted p-values. (F) As measured by flow cytometry, the geometric MFI of Tbet
in CD4+ cells increases on a per-cell basis with increasing signal strength. Note that MFI of the entire population of CD4+ cells is shown, as Tbet
distribution is unimodal. (G) Similarly, per-cell protein levels of IRF4 increase with increasing signal strength when measured with flow cytometry. (p-
values based on Student’s t test; *p<0.05, **p<0.01, ***p<0.001.)
DOI: 10.7554/eLife.10134.005
The following figure supplement is available for figure 2:
Figure supplement 1. RNA-Sequencing reveals graded expression of activation signature genes.
DOI: 10.7554/eLife.10134.006
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Figure 3. Single-cell RNA levels reflect whole-population levels for a subset of genes. (A) RNA flow cytometry was used to determine the single-cell
levels of RNA transcripts for Irf4 across the five peptide conditions. The mean fluorescence intensity of the Irf4 RNA probe increases across the five
Figure 3 continued on next page
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each condition reflected only the activated cells, and thus were not diluted by non-responder cells.
As with the whole-population RNA-seq, we used PCA to determine the primary axes of variation
across the four samples for which CD69+ cells could be collected. (Insufficient responder cells could
be retrieved from the no-peptide condition for sequencing.) Across the four treated samples, the
first principal component again sorted the conditions according to the relative strength of TCR sig-
naling (Figure 3B). Looking at the genes composing the top 10% of PC1, we saw, as with the whole-
population RNA-seq, that gene expression patterns largely reflected the same trend, increasing with
increasing TCR signal (Figure 3C, Figure 3—figure supplement 1E).
To assess what genes made up the activation signature seen in PC1, we performed GO analysis
on the genes in the top 10% of PC1. As with the whole-population data, genes associated with cell
metabolic processes like translation and RNA biosynthesis were enriched (Figure 3D), indicating
that the expression of genes in key cellular activation pathways increases with increasing TCR signal-
ing on a per-cell basis as well as at the population level. In contrast to the whole-population data,
there was a group of genes that were near maximally activated in CD69+ cells treated with the low
concentration of K99A and exhibited similar expression across all treatment conditions. This ‘digital’
pattern is illustrated in Figure 3E for the 100 most highly induced/most consistently expressed
genes and for representative genes in Figure 3—figure supplement 1F. GO analysis demonstrated
that this digital cluster of genes was enriched for immune signaling terms (Figure 3F). Expression
profiles for representative mRNAs in the translation initiation factor and the ribosome biogenesis
groups are illustrated in Figure 3G,H and Figure 3—figure supplement 1E, and representative
mRNAs in the digital group are illustrated in Figure 3I and Figure 3—figure supplement 1F.
Thus, the graded increase in expression of activation signature genes at the population level is a
reflection of both frequency of responding cells and incremental increases in expression levels on a
single-cell level for at least a subset of genes, including key cellular metabolism genes.
An activation score ranks CD4+ T cell samples by activation status
Given that PC1 was able to distinguish between the five conditions according to activation state, we
extracted the genes from the top and bottom of the whole-population PC1 that were consistent
across replicates to use as a general-purpose activation score able to correctly rank the five condi-
tions by TCR signal (Figure 4A). We compared samples from several publicly available datasets, and
the activation score was able to quantitatively rank conditions within a given experiment set such
that activated and naı¨ve CD4+ T cells could be distinguished and further that the effects of various
Figure 3 continued
conditions assayed via RNA flow cytometry. Data is representative of two technical and two biological replicates. (B) Treated cells were sorted, and
RNA-sequencing was performed on the CD69+ cells from each peptide condition such that the effect of responder frequency was controlled. PCA of
the genes that changed between any two samples reveals that the primary axis of variation (PC1, shown along the x-axis) orders the four conditions that
had any retrievable CD69+ cells by increasing TCR signal strength: low-dose, low-affinity (10 mM K99A); high-dose, low-affinity (100 mM K99A); low-dose,
high-affinity (0.1 mM PCC); and high-dose, high-affinity (10 mM PCC). (C) As with the whole-population RNA-sequencing data, looking at the top 10% of
genes along PC1 revealed an expression profile that reflects the analog signal seen with external activation markers such as CD25 and CD69. Each blue
line represents a gene, with reads per kilobase per million (RPKM) normalized from 0 to 1 across the five conditions. (D) Gene Ontology (GO) analysis of
the genes in the top 10% of PC1 shows enrichment for terms related to metabolic processes such as translation and RNA biosynthesis. (E) There was
additionally a digital cluster of genes identified that showed threshholding behavior upon cell activation. For the digital cluster, expression levels were
low in the control CD69- cells, and universally higher across all CD69+ samples. The peptide conditions are sorted along the x-axis, and the normalized
RPKM for the 100 most highly induced/most consistently expressed genes in the cluster is shown along the y-axis. (F) GO analysis of the genes in the
digital cluster shows an enrichment for terms related to immune signaling pathways. (G) RPKM levels for several genes classified as ’translation initiation
factors’ are shown. For most of the genes, expression is low for the CD69- control, and increases in an analog fashion across the CD69+ cells from each
treated condition. The peptide conditions are sorted along the x-axis, and RPKM for each gene is shown along the y-axis. (H) RPKM levels for several
genes in the ’ribosome biogenesis’ GO category are shown. Expression is low for the CD69- control, and increases in an analog fashion across the
CD69+ cells from each treated condition. The peptide conditions are sorted along the x-axis, and RPKM for each gene is shown along the y-axis. (I)
RPKM levels for several genes indicative of the digital cluster are shown. Expression is low for the CD69- control, but relatively level across all CD69+
samples. The peptide conditions are sorted along the x-axis, and RPKM for each gene is shown along the y-axis.
DOI: 10.7554/eLife.10134.007
The following figure supplement is available for figure 3:
Figure supplement 1. RNA flow cytometry for Irf4 shows graded increases.
DOI: 10.7554/eLife.10134.008
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Figure 4. PC1 can be used to rank arbitrary CD4+ T cell data sets. (A) An activation score derived from the top and bottom genes along PC1 ranks the
five conditions according to TCR signaling strength. The score correctly captures that 100 mM K99A and 0.1 mM PCC are very similar in activation status.
Figure 4 continued on next page
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genetic perturbations of CD4+ T cell responses could be observed. For example, the activation
score correctly recapitulated the findings that polarized helper subsets of CD4+ T cells were more
pro-inflammatory than unstimulated cells or induced and natural regulatory T cells (Wei et al., 2009)
(Figure 4B); that at the population level plate-bound anti-CD3 and anti-CD28 induced stronger acti-
vation signals than APCs plus antigen (Tan et al., 2014) (Figure 4C); that costimulation was impor-
tant for achieving higher activation states but checkpoint inhibitors could block this effect
(Wakamatsu et al., 2013) (Figure 4D); that knockout of Trim28, a molecule necessary for optimal
IL2 production, diminished CD4+ T cell activation status (Chikuma et al., 2012) (Figure 4—figure
supplement 1A); and that acute LCMV infection produced more robust activation in CD4+ T cells
than chronic infection (Doering et al., 2012) (Figure 4—figure supplement 1B).
In order to test the value of the activation score, we used it to rank naı¨ve CD4+ T cells from 39
inbred mouse strains (Mostafavi, 2014) (Figure 4E). The activation score quantified the variability in
the isolated CD4+ T cells according to activation status, revealing that the genetic differences
between the strains yielded different levels of activity even under unstimulated conditions. As would
be predicted by known strain phenotypes, C57BL/6 cells were more activated than most strains,
while BALB/c mice were less activated than most strains. The lupus-prone MRL strain and the type 1
diabetes-prone NOD strain had cells that ranked as relatively activated, whereas the type 1 diabe-
tes-resistant NON strain had a relatively low activation score.
The strain with the highest activation score, DBA/2, had top-quartile expression of more than half
of the activation signature genes (p=7.4e-30 by chi-squared test). These included a number of
immune effectors such as Irf4, Cd25, Il2rb, Nfkb1 (p105/p50), and Nr4a1 (Nur77), as well as 17 of 32
genes from the protein biosynthesis group and 5 of 12 genes from the molecular chaperone group.
Differences in the immune phenotypes of the DBA/2 strain, such as resistance to malaria, have been
largely attributed to B cell-dependent mechanisms (Bakir et al., 2006), but the activation score here
indicates that naı¨ve CD4 T cells from DBA/2 mice are skewed toward an activated phenotype.
Figure 4 continued
Note that the score ranks samples within an experiment, but is not an absolute metric for comparing across experiment groups. (B) The activation score
can be used to compare arbitrary CD4+ T cell data sets. Here, activation scores were calculated for microarrays from helper T cell subsets, and they
demonstrate that naı¨ve cells and native regulatory T cells (nTregs) are less classically activated than Th1, Th2, and Th17 polarized subsets. (C) The
activation score captures the fact that plate-bound anti-CD3 and anti-CD28 stimulation of helper T cell subsets results in stronger signaling than
antigen as presented by APCs. (D) CD4+ T cells were subjected to a variety of stimulatory or inhibitory treatments: anti-CD3 alone, or anti-CD3 with
anti-CD28, anti-BTLA, anti-CD80, anti-CTLA4, anti-ICOS, or anti-PD1. Gene expression profiles at early (1 hr and 4 hr) and late (20 hr and 48 hr) time
points yield activation scores in line with the characterization of CD28, BTLA, CD80, and ICOS as co-stimulatory, and CTLA4 and PD1 as inhibitory.
Although it might be expected that anti-CD80 would have an inhibitory effect, these results are in line with the conclusions from the originally
published analysis. (E) Naı¨ve CD4+ splenocytes were isolated from 39 mouse strains. Using the PC1-derived activation score, we can rank the CD4+
cells from each strain as either more or less activated under basal conditions. Using the activation score, we recapitulate the finding that C57Bl6 mice
have more pro-inflammatory cells than BALB/c mice. The highest scoring strain, DBA/2, shows top-quartile expression of immune effectors as well as
protein biosynthesis genes. (P-values based on Student’s t test; *p<0.05, **p<0.01, ***p<0.001.)
DOI: 10.7554/eLife.10134.009
The following figure supplement is available for figure 4:
Figure supplement 1. PC1 can be used to rank arbitrary CD4+ T cell data sets.
DOI: 10.7554/eLife.10134.010
Table 1. Pairwise overlap between the H3K4me2 peaks. Each cell contains the count of overlapping peaks where each condition
shown has at least 40 tags (normalized). In the diagonal is the total number of peaks with at least 40 tags for the given condition.
No Peptide 10 mM K99A 100 mM K99A 0.1 mM PCC 10 mM PCC
No Peptide 16012 14951 12487 14783 13105
10 mM K99A 15616 12549 14838 13192
100 mM K99A 12695 12603 12247
0.1 mM PCC 15569 13281
10 mM PCC 13444
DOI: 10.7554/eLife.10134.011
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Figure 5. Primed enhancers are pre-existing, but gain activation markers with treatment. (A) Comparing primed enhancers marked by H3K4me2 peaks
reveals strong correlation between untreated and treated samples. Normalized tag counts in the No Peptide condition are plotted against those in a 1
Figure 5 continued on next page
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Three of four wild-derived strains had low activation scores: CAST, MSM, and WSB mice. All three
of these wild-derived strains had bottom-quartile expression of the immune effectors Irf1, Irf8, Stat1,
Nfkb1, and Tnf, indicating that these CD4+ T cells possess a less inflammatory gene expression pro-
file under homeostatic conditions.
Thus, the activation score serves as a widely applicable and quantitative measure of CD4+ T cell
activity, and can be used to assess the relative activation status of a variety of CD4+ T cell samples.
We have developed a publically available, open source tool (see Materials and methods) to facilitate
the scoring and ranking of datasets by interested parties.
Pre-existing enhancers are leveraged to activate genes
In order to better understand the changes in genome-wide expression patterns that occurred with
TCR stimulation, we compared enhancer landscapes with and without stimulation. We first per-
formed ChIP-sequencing for H3K4me2, a marker of primed and active promoters and enhancers
(He et al., 2010; Kaikkonen et al., 2013), across the five conditions. By and large, the H3K4me2-
marked regions across the five conditions were very similar (Table 1), with a comparison of tag
counts associated with specific genomic regions under no peptide or 1 mM PCC illustrated in
Figure 5A. Though there were some enhancers showing at least two-fold change in H3K4me2 tag
counts across conditions, these regions were at the lower end of the tag count range and therefore
differences were not significant (Figure 5A, red points). Thus, the gene expression and phenotypic
changes seen after activation were not due to selection of new signal-dependent enhancers.
At promoters, H3K4me2 marks were shared across the five conditions, but activation signature
genes showed spreading of the H3K4me2 mark along the body of the gene after TCR stimulation. In
contrast, H3K4me2 peaks were narrow and focal for the untreated condition at many of these genes.
This effect can be seen at Cd69 (Figure 5—figure supplement 1A) and Irf4 (Figure 5—figure sup-
plement 1B), resulting in a global increase of the ratio of gene body tags to promoter tags at activa-
tion signature genes (Figure 5—figure supplement 1C) but not genes in the bottom 10% of PC1
(Figure 5—figure supplement 1D). This implies that the process of activating these genes subse-
quent to TCR stimulation induces deposition of the dimethyl mark along the body of the genes as
they are transcribed.
Motif analysis reveals lineage-determining and signal-dependent TFs
We used de novo motif finding (Heinz et al., 2010) to identify lineage-determining transcription fac-
tors (LDTFs), also known as pioneer factors or master regulators, which establish cell-type-specific
enhancer landscapes, and determine the available open chromatin for subsequent binding of signal-
dependent transcription factors (SDTFs) (Garber et al., 2012; Heinz et al., 2013; Mullen et al.,
2011; Soufi et al., 2012; Trompouki et al., 2011). The top motif was an ETS motif (Figure 5B),
capable of being bound by a number of ETS factors that are expressed in CD4+ T cells, including
Figure 5 continued
mM PCC condition, with red dots coloring those that are more than two-fold up-regulated in the 1 mM PCC condition. The up-regulated enhancers are
both few in number and low in tag count. (B) De novo motif finding identifies lineage-determining transcription factor (LDTF) motifs among primed
enhancers shared by the five conditions. An ETS motif is most prominent, and a RUNX motif is likewise highly enriched over the randomly selected
background. Both ETS and RUNX factors play important roles in T cell development. (C) Among primed enhancers shared by all five conditions,
including the untreated condition, pro-inflammatory transcription factor motifs are enriched. An IRF family motif, AP-1 family motif (represented by
BATF), and NF-kB motif (represented by REL) are all significantly enriched among shared enhancers marked by H3K4me2. (D). Comparing H3K27Ac tag
counts at enhancers in No Peptide as compared to 1 mM PCC treatment reveals that many enhancers see increasing H3K27Ac deposition upon
stimulation. Points in red indicate greater than two-fold increase in tags upon treatment. (E) Enhancers that are more active upon stimulation, as
determined by greater than two-fold H3K27Ac tags in 1 mM PCC treatment as compared to No Peptide, are enriched for pro-inflammatory transcription
factor motifs. BATF, an AP-1 family member, and NF-kB are most prominent. (F) Enhancers that are more active with stimulation are enriched near
activation signature genes, as can be seen with this enhancer upstream of the activation signature gene Il2ra (CD25). (G) Enhancers upstream of the
activation signature gene Cd69 show an increase in H3K27Ac deposition upon treatment with 1 mM PCC. (H) Genome-wide, deposition of H3K27Ac, a
marker of transcription factor activity, reflects increasing TCR signal strength at the binding sites of AP-1 family members, including BATF.
DOI: 10.7554/eLife.10134.012
The following figure supplement is available for figure 5:
Figure supplement 1. Primed enhancers are pre-existing, but gain activation markers with treatment.
DOI: 10.7554/eLife.10134.013
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Ets1, Ets2, and Elf1 (Anderson et al., 1999). These enhancers tend to be shared across similar cells
as well as thymic T cell precursors (Heinz et al., 2010; Zhang et al., 2012). Similarly, Runx factors
play an important role in T cell development (Wong et al., 2011), and correspondingly the Runx
family motif was highly enriched among primed enhancers.
Several known motifs for SDTFs were also enriched among the H3K4me2-marked enhancers
(Figure 5C), including an Interferon Regulatory Factor (IRF) motif. Although IRFs respond to inter-
feron signaling (Ozato et al., 2007), and would not be expected to be active in unstimulated cells
(Murphy et al., 2013; Glasmacher, 2012; Li et al., 2012), it is possible that the IRF motif is a ’mem-
ory’ of states of activation during the development of CD4+ T cells, and indeed IRF motifs can be
found in several related cell types and multiple stages of thymocyte development (Figure 5—figure
supplement 1E), suggesting that the primed enhancers in naı¨ve CD4+ T cells are predisposed to act
as binding sites for key SDTFs (Heinz et al., 2010; Zhang et al., 2012; Buecker et al., 2014;
Mikkelsen et al., 2010; Mishra et al., 2014; Vahedi et al., 2012). Similarly, an AP-1 motif and an
NF-kB motif were significantly enriched in primed enhancers (Figure 5C), corresponding with the
fact that TCR signaling greatly increases activity of both of these transcription factors (Huang and
Wange, 2004; Rinco´n and Flavell, 1994).
Given that H3K4me2-marked regions were not substantially changed across the five conditions,
we next performed ChIP-sequencing for H3K27Ac, a marker for active enhancers (Creyghton et al.,
2010), under a stimulated condition (1 mM PCC) and the unstimulated condition. In contrast to
H3K4me2, a substantial portion of enhancers exhibited increases in the H3K27Ac activation mark
(Figure 5D, Table 2). The union set of enhancers was enriched for a similar set of motifs as the
primed enhancers (Figure 5—figure supplement 1F,G). Enhancers that became more active with
TCR engagement were highly enriched for both AP-1 and NF-kB motifs (Figure 5E). Further, this
group of enhancers was more likely to be proximal to activation signature genes than would be
expected at random (p-value = 2.0e-20 by chi-squared test). These enhancers included, for example,
those upstream of Il2ra (CD25; Figure 5F) and Cd69 (Figure 5G).
To investigate whether there was a quantitative relationship between TCR signal strength and
enhancer activation, we performed independent ChIP-Seq for H3K27Ac in response to both pepti-
des at low and high concentrations. Given the prevalence of the AP-1 motif in the signal-responsive
enhancers, we analyzed H3K27Ac tag counts at AP-1 binding sites genome-wide using publicly avail-
able ChIP-Sequencing data from in vitro activated TH17 cells (Li et al., 2012). There was an increase
in H3K27Ac deposition at AP-1 binding sites that reflected the graded strength of TCR signaling
(BATF shown in Figure 4H; other AP-1 family members in Figure 5—figure supplement 1H,I), indi-
cating that AP-1 binding sites became more active in a graded manner corresponding to increasing
TCR signaling. Graded changes in H3K27Ac were much less pronounced at CTCF binding sites,
which occur at enhancers but are also more broadly distributed and play roles in establishing bound-
ary elements.
Super-enhancers prime signaling genes
We next looked at changes in super-enhancers (Hnisz et al., 2013; Love´n et al., 2013;
Whyte et al., 2013) upon activation using the H3K27Ac mark. Most super-enhancers (approximately
450 out of 700 total) identified were shared by both the unstimulated and stimulated conditions. GO
analysis of genes nearby the shared super-enhancers showed enrichment for leukocyte activation
Table 2. Pairwise overlap between the H3K27Ac peaks. Each cell contains the count of overlapping peaks where each condition
shown has at least 40 tags (normalized). In the diagonal is the total number of peaks with at least 40 tags for the given condition.
No Peptide 10 mM K99A 100 mM K99A 0.1 mM PCC 10 mM PCC
No Peptide 6410 3591 5791 5988 5977
10 mM K99A 3671 3557 3594 3584
100 mM K99A 8877 8699 8789
0.1 mM PCC 9867 9368
10 mM PCC 10021
DOI: 10.7554/eLife.10134.014
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Figure 6. Super-enhancers prime T cell activation genes. (A) Gene Ontology (GO) analysis of genes nearest to the ~450 super-enhancers shared by
treated and untreated conditions show enrichment for T cell activation genes. P-values shown are Benjamini-Hochberg adjusted p-values. (B) H3K27Ac
marks a large super-enhancer around the lineage-determining transcription factor Ets1 in both the No Peptide and 1 mM PCC conditions. The super-
enhancer spans the ~600 kbp region shown. (C) The ~400 kbp super-enhancer region encompassing Cd28, Ctla4, and Icos is marked by H3K27Ac in
both treated and untreated conditions. (D) Despite being heavily marked by H3K27Ac in both untreated and treated conditions, shared super-
enhancers near activation signature genes show a significant gain in H3K27Ac tags in response to stimulation as compared to the shared super-
enhancers not proximal to activation signature genes. In other words, basally primed super-enhancers near activation signature genes see significant
increases in activity upon stimulation, correlating with increased gene expression at the activation signature genes. (E) Some regions of H3K27Ac
deposition required TCR stimulation to pass the super-enhancer threshold, as can be seen here at the ~60 kbp region encompassing BATF, an AP-1
family member. While H3K27Ac is clearly present under basal conditions, there is a substantial increase in enhancer activity upon treatment with 10 mM
PCC. (F) Il2ra (CD25) shows increased enhancer activity and formation of a super-enhancer in the treated condition. (G) Similarly, the region surrounding
Tbx21 (Tbet) shows substantial increases in activity subsequent to stimulation, resulting in the formation of a super-enhancer. (p-values based on
Student’s t test; *p<0.05, **p<0.01, ***p<0.001).
DOI: 10.7554/eLife.10134.015
The following figure supplement is available for figure 6:
Figure supplement 1. Super-enhancers prime T cell activation genes.
DOI: 10.7554/eLife.10134.016
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Figure 7. ERK signaling translates TCR signal strength into graded gene expression. (A) ERK phosphorylation is a measure of ERK pathway activity.
Flow cytometry for phospho-ERK after 3.5 hr of co-culturing shows that, on a per-cell basis, increasing signal strength yields increasing levels of
phospho-ERK among CD4+ phospho-ERK+ cells. (B) ERK pathway activation is upstream of the transcription factor AP-1. ChIP-sequencing tags for four
Figure 7 continued on next page
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genes as well as Pleckstrin homology genes, which are critical components of a number of kinase sig-
naling pathways downstream of the TCR (Figure 6A), indicating that super-enhancers in CD4+ T
cells prime genes important for inflammatory signaling. These basally-primed super-enhancers
included regions near key T cell genes such as Ets1 (Figure 6B), Runx1 (Figure 6—figure supple-
ment 1A), Ctla4/Icos/CD28 (Figure 6C), and Irf4 (Figure 6—figure supplement 1B). Notably, even
though many of the super-enhancers exist prior to stimulation, super-enhancers near activation sig-
nature genes show an increase in H3K27Ac signal subsequent to TCR signaling (Figure 6D).
118 of the 568 super-enhancers identified after TCR stimulation were not identified as super-
enhancers in the unstimulated condition. The super-enhancers that required TCR signaling were
enriched for leukocyte activation genes (Benjamini-Hochberg adjusted p-value = 4.6e-7) crucial for T
cell activation, including Batf (Figure 6E), Il2ra (CD25, Figure 6F), Tbx21 (Tbet, Figure 6G), Lag3
(Figure 6—figure supplement 1C), and Stat5b (Figure 6—figure supplement 1D).
ERK translates TCR signal strength downstream
The Ras/Raf/Mek/Erk pathway downstream of the TCR activates the AP-1 transcription factor family
through a series of phosphorylation events and transcriptional induction of immediate-early genes
(Murphy et al., 2013; Rinco´n and Flavell, 1994). Given the fact that the AP-1 motif was enriched at
enhancers showing increasing activity and the fact that AP-1 binding sites saw increasing H3K27Ac
deposition, we sought to determine whether AP-1 and the ERK pathway were relevant to the
increasing expression of activation signature genes across the conditions. We first compared the
level of phosphorylated ERK (p-ERK) in each condition using flow cytometry, and found that, like
CD69 and CD25, the amount of p-ERK in the p-ERK+ cells varied on a per-cell basis in each condi-
tion, increasing with TCR signal strength (Figure 7A). Frequency of pERK+ cells also differed across
peptide conditions (Figure 7—figure supplement 1A), indicating that both frequency and single-
cell response level play a role in the effect of MEK inhibitors. As the increasing levels of p-ERK paral-
leled the general pattern of expression of the activation signature genes, we assessed binding fre-
quencies of AP-1 factors in the gene promoters of the activation signature genes as compared to
the bottom 10% of PC1 genes, and found that activation signature genes showed a significantly
higher frequency of AP-1 binding (Figure 7B). This enrichment for AP-1 binding was not dependent
on the expression level of the genes in each group, as segmenting the genes by RPKM showed the
same pattern (Figure 7—figure supplement 2).
ERK pathway activation and AP-1 binding therefore seemed to correlate well with the graded
profile of activation signature genes and the increasing activation score across the samples. In order
to determine whether the gradual increase in ERK pathway activation was causal in translating TCR
signaling into gradual increases in the expression of activation signature genes, we pretreated the
CD4+ T cells with a low-dose MEK inhibitor (MEKi). MEK inhibition upstream of ERK was capable of
suppressing p-ERK activity entirely, and titration of MEKi yielded intermediate levels of p-ERK on a
per-cell basis (Figure 7—figure supplement 1B).
Figure 7 continued
AP-1 family members (BATF, cJun, JunB, and JunD) in Th17 cells shows that there is an enrichment for AP-1 binding near the promoters (plus or minus
1,000 bp from the TSS) of activation signature genes (top 10% of PC1) as compared to all genes or the genes in the bottom 10% of PC1. (C) A MEK
inhibitor that dampens signaling upstream of the ERK pathway preferentially diminishes expression of activation signature genes, as seen in the fact
that the RPKM of genes in the top 10% of PC1 is significantly reduced with treatment. (D) The reduction of RPKM seen with the activation signature
genes is not a general effect, as the RPKM of the genes in the bottom 10% of PC1 are not significantly affected by MEK inhibitor treatment. (E) We
quantified the effect of MEK inhibitor treatment using the activation signature score. Treatment with the MEK inhibitor reduces the activation signature
score for all samples. (F) Schematic of the ERK-AP-1 axis. See text for details. (p-values based on Student’s t test; *p<0.05, **p<0.01, ***p<0.001).
DOI: 10.7554/eLife.10134.017
The following figure supplements are available for figure 7:
Figure supplement 1. ERK signaling translates TCR signal strength into graded gene expression.
DOI: 10.7554/eLife.10134.018
Figure supplement 2. AP-1 enrichment is independent of expression level.
DOI: 10.7554/eLife.10134.019
Figure supplement 3. AP-1 enrichment is independent of expression level.
DOI: 10.7554/eLife.10134.020
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Low-dose MEK inhibition decreased the levels of the extracellular signaling marker CD69 (Fig-
ure 7—figure supplement 1C), which was in the top 10% of PC1, but this suppression was not uni-
versal, as CD4, an example of a gene not in the top 10% of PC1, was not significantly affected
(Figure 7—figure supplement 1D). In order to see if this preferential suppression of activation sig-
nature genes was widespread, we performed RNA-seq on the five conditions after pretreatment
with MEKi at IC50 (0.5 mM). If TCR signaling strength upstream of pERK yields graded levels of ERK
that are in turn essential for the graded levels of activation response genes, then reduction of pERK
levels should move each sample downwards in activation score, such that the high-dose, high-affinity
case looks like the low-dose, high-affinity; the low-dose, high-affinity looks like the high-dose, low-
affinity; and so on.
Accordingly, MEK inhibition at IC50 decreased expression of activation signature genes
(Figure 7C, Figure 7—figure supplement 1E), but, as with extracellular expression of CD69, this
effect was selective; expression of genes in the bottom 10% was increased or unchanged
(Figure 7D, Figure 7—figure supplement 1F). The decrease in expression among genes in the top
10% of PC1 upon MEKi treatment was not dependent on expression level of the genes, as the effect
was consistent when genes were segmented by RPKM level (Figure 7—figure supplement 3). Using
the activation score to assess total T cell activation status, we found that MEKi shifted each sample
down in score (Figure 7E), as would be expected if the graded levels of pERK seen with each condi-
tion were prescriptive of the activation status of the condition. Thus, graded levels of pERK down-
stream of the TCR help to translate the analog activation signal to graded levels of enhancer activity
and gene expression genome-wide (Figure 7F).
Discussion
Understanding how CD4+ T cells respond to ligands of different doses and affinities is critical to
understanding the nature of the adaptive immune response to both pathogens and self. Here, we
have shown that the traditional model of a purely digital TCR response is too simple; on a per-cell
basis, stronger TCR signals result in higher levels of phosphorylated ERK, a proportional increase in
enhancer acetylation, and quantitative increases in activation markers such as CD69 and CD25
(Figure 7F). As a result of both these single-cell differences and the increasing frequency of respon-
dent cells, varying the dose or the affinity of the pMHC-TCR interaction results in a gene expression
profile that is graded corresponding to increasing strength of TCR signaling. We observed no evi-
dence for Th1/Th2 skewing as a function of peptide dose/affinity, which may reflect the specific pep-
tides used for stimulation. Notably, the predominance of PC1 and the graded gene expression
patterns together indicate that dose and affinity are not interpreted separately downstream of the
TCR, but rather overall signaling strength sets the level of activation across the population. A similar
conclusion has been drawn by looking at the sum of activation parameters induced by antigen-, co-
stimulatory- and cytokine-receptors (Marchingo, 2014).
Prior analysis of T cell responses at the single cell level showed that single T cell engagement of
different numbers of identical peptide agonists (titration of signal strength) resulted in digital
responses read out as increasing numbers of T cells producing the same amount of TNF or IL2 pro-
tein (Huang et al., 2013). Intriguingly, different levels of responses were seen when naı¨ve cells were
compared with blast and memory cell responses, such that the rate of TNF and IL2 synthesis in blasts
and memory cells was nearly ten-fold higher than in naı¨ve cells. Our findings are consistent with
these earlier studies in that TNF and IL2 are members of the ‘digital’ class of RNAs identified in
CD69+ cells (Figure 3—figure supplement 1E). Furthermore, the increase in expression of genes
involved in protein expression revealed by the present studies could at least partly explain the
observation that the rates of TNF and IL2 protein production are increased in blasts and memory
cells in comparison to naı¨ve cells. The analogue increase in protein biosynthetic machinery could
also at least partly explain the observation that CD69 expression is digital at the level of mRNA but
analogue at the level of protein expression (Figure 1A, Figure 3—figure supplement 1F).
Ranking genes along a primary axis of variation allowed us to extract a set of activation signature
genes that increase in a graded fashion at the population level proportionally to TCR signal strength,
and further to establish an activation score that can rank arbitrary CD4+ T cell samples by the
strength of signaling. The data presented here therefore gives us a greater understanding of the
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CD4+ T cell response to ligands of varying concentrations and affinities, and informs our understand-
ing of CD4+ T cell activation under diverse conditions.
Significant differences in primed enhancers have been demonstrated under several stimulating
conditions in macrophages, and demonstrate the ability of cells to quickly remodel chromatin to ini-
tiate particular gene expression programs (Kaikkonen et al., 2013; Ostuni et al., 2013). Surpris-
ingly, we did not find significant changes in the primed enhancer landscape upon TCR activation in
CD4+ T cells. Similarly, even the more labile activation mark H3K27Ac was largely similar across con-
ditions, with many activation genes marked as super-enhancers even before stimulation. While it
remains to be seen whether non-TCR signaling pathways or polarizing conditions induce more dra-
matic changes, the data presented here indicates that the CD4+ T cell enhancer landscape is largely
pre-established, with subsets of H3K4me2-marked enhancers increasing in activity, but little in the
way of de novo enhancer establishment. This finding helps to explain the speed and plasticity of the
CD4+ T cell response (Zhou et al., 2009)—if all enhancers are primed basally, and many are even
activated basally, then pro-inflammatory transcription factors can bind at established enhancers and
initiate new gene expression programs with minimal additional transcriptional machinery.
Both the frequency of AP-1 binding and the level of pERK correlate with the strength of TCR sig-
naling and the graded expression of activation signature genes. At least one of the feedback loops
leading to digital TCR signaling, the son of sevenless (SOS) positive feedback loop, exists upstream
of ERK, and it has been shown in thymocytes that pERK signaling is digital (Das et al., 2009;
Daniels et al., 2006; Prasad et al., 2009). However, studies focused on EGFR signaling upstream of
ERK indicated that discrete pulses of ERK activity result in quantitative levels of downstream signal-
ing activity (Albeck et al., 2013). Our analog results for pERK can be interpreted to support the
notion that TCR signaling in thymocytes functions differently than TCR signaling in mature T cells.
Notably, both Themis and SOS, two key components of digital signaling in thymocytes, do not seem
to be critical to mature T cell signaling (Fu et al., 2013; Warnecke et al., 2012).
The graded levels of pERK in CD4+ T cells prove important for downstream enhancer and gene
activity. We have here established a mechanistic link between the level of ERK signaling and the
expression patterns of activation signature genes by using an inhibitor of MEK, upstream of ERK.
Low-dose MEK inhibition selectively decreased expression of the activation signature genes such
that the activation score under the inhibited conditions was incrementally decreased. This indicates
that the analog levels of pERK seen on a per-cell basis are translated at a population level into
increased enhancer and gene activity, and that ’turning down’ pERK levels selectively diminishes the
activation status of the cells. This finding is of particular interest in light of the clinical availability of
numerous RAF, MEK, and ERK inhibitors (Zhao and Adjei, 2014; Samatar and Poulikakos, 2014).
Our findings suggest that low-dose ERK pathway inhibition could be used to selectively decrease
the activity of activation signature genes in CD4+ T cells, achieving low-level immunosuppression
without killing T cells or completely removing their ability to respond to TCR signaling. Further, the
effect of MEK inhibitors on CD4+ T cells raises questions about the immunosuppressive effects of
using MEK inhibitors in cancer treatment, especially as current clinical trials combine MEK inhibitors
with checkpoint-blockade inhibitors (Zhao and Adjei, 2014; Vella et al., 2014).
Notably, NFkB is one of many transcription factors known to play important roles in T cell biol-
ogy, and indeed we find a kB motif enriched among enhancers that are responsive to stimulation
(Figure 5E). Further research as to the relationship between the strength of TCR signaling and other
signal-dependent transcription factors such as NF-kB and NFAT is warranted.
In sum, this study makes use of a unique model system to dissect the transcriptional responses of
CD4+ T cells to increasing strength of signaling, and demonstrates that analog levels of pERK within
the context of digital TCR signaling flow downstream to result in graded gene expression profiles
and enhancer landscapes that can be used to characterize CD4+ T cell signaling at large.
Materials and methods
Mice
AND mice on a B10.BR background were received from Dr. Michael Croft (Rogers and Peptide
dose, 1999; Rogers et al., 1998) and bred in a specific pathogen free facility. All animal
Allison et al. eLife 2016;5:e10134. DOI: 10.7554/eLife.10134 19 of 28
Research article Computational and systems biology Immunology
experiments were in compliance with the ethical standards set forth by UC San Diego’s Institutional
Annual Care and Use Committee (IUCAC).
Cells
Spleens were extracted and manually digested. CD11c+ cells were isolated using Miltenyi Biotec
Inc. (San Diego, CA) MACS magnetic cell separation with positive selection for CD11c (CD11c, Biole-
gend, cat. no. 117304). Subsequently, the CD11c- splenic fraction was used to negatively select for
naı¨ve CD4+ T cells using the Miltenyi MACS system with the following antibodies: CD11c (Biole-
gend, cat. no. 117304); CD45R (eBioscience, cat. no. 13-0452-86); CD11b (eBioscience, cat. no. 13-
0112-86); CD25 (eBioscience, cat. no. 36-0251-85); CD49b (eBioscience, cat. no. 13-5971-85); CD69
(eBioscience, cat. no. 13-0691-85); CD8a (eBioscience, cat. no. 13-0081-86); Ly-6G (eBioscience, cat.
no. 13-5931-86); MHC class II (eBioscience, cat. no. 13-5321-85); TER-119 (eBioscience, cat. no. 13-
5921-85). CD11c+ and CD4+ cells were cultured at a ratio of 1:2 in 96-well round-bottom plates for
24 hr, 108 hr (for proliferation assay), or 3.5 hr (for ERK phosphorylation staining). Peptides were
added at indicated concentrations with the CD11c+ and CD4+ cells in DMEM supplemented with
10% Fetal Bovine Serum. For sequencing experiments, CD4+ cells were re-isolated from the culture
using the Miltenyi MACS system and the same set of antibodies as above less CD25 and CD69. For
phospho-ERK staining, whole splenic cells were used, rather than purified CD11c+ and CD4+ cells.
Peptides
Peptides were ordered from Peptide 2.0 (Chantilly, VA) with the following amino acid sequences
(Rogers and Peptide dose, 1999; Rogers et al., 1998):
PCC – KAERADLIAYLKQATAK
K99A – KAERADLIAYLAQATAK
Y97K – ANERADLIAKLKQATK
K99E – ANERADLIAYLEQATK
MCC – ANERADLIAYLKQATK
Lyophilized peptides were resuspended in water, and added at the indicated concentrations to
the cell cultures. Unstimulated CD4+ cells received an equivalent amount of water alone.
Flow cytometry
Flow cytometry was performed on a LSR II and LSR Fortessa, both from BD Biosciences (San Jose,
CA). Cells were stained as per manufacturers’ protocols with the following antibodies: CD4-APC
(eBioscience, cat. no. 17-0042-83); CD4-PE-Cyanine7 (BioLegend, cat. no. 116016); CD69-FITC (eBio-
science, cat. no. 11-0691-82); CD25-PE (eBioscience, cat. no. 12-0251-82); Valpha11-FITC (BD Phar-
mingen, cat. no. 553222); Vbeta3-PE (BD Pharmingen, cat. no. 553209); CD11c-PE-Cyanine7
(eBioscience, cat. no. 25-0114-82); IRF4-PerCP-Cy5 (eBioscience, cat. no. 46-9858-80); Tbet-PE
(Santa Cruz Biotechnology, cat. no. SC-21749); CD122-PE (BioLegend, cat. no. 105905); Ly6a-APC-
Cyanine7 (BioLegend, cat. no. 108125); CD200-APC (BioLegend, cat. no. 123809); TNFSF11-APC
(BD Biosciences, cat. no. 560296); phospho-ERK-Alexa Fluor 488 (Cell Signaling, cat. no. 4344S).
Live/dead staining was performed using Fixable Aqua (Life Technologies, cat. no. L34957; or Biole-
gend, cat. no. 423102). Cells were gated on CD4+, Aqua- cells. For phosphor-ERK staining, permea-
bilization was performed using BD Phosflow Perm Buffer III (cat. no. 558050) and BD Fix Buffer I (cat.
no. 557870). Analysis was performed with FlowJo v10.6 (Tree Star; Ashland, OR). All flow cytometry
results shown are representative of at least two biological replicates, and the results shown in Fig-
ure 1 were reflected with samples held out of each high-throughput sequencing assay.
mRNA flow cytometry
CD11c+ cells and naı¨ve CD4+T cells were isolated form spleens of AND mice using magnetic sepa-
ration as described above. CD11c+ cells and CD4+ T cells were cultured at a ratio of 1:2 in 96 –well
round bottom plates with various concentrations of K99A (10 mM and 100 mM) and PCC (0.1 mM and
10 mM).
After 22 hr, cells were harvested and mRNA expression of Irf4 was analyzed on single cell level by
flow cytometry in combination with CD4, and CD69 protein staining, using FlowRNA II Assay kit
(Affymetrix eBioscience) according to manufacturer’s protocols (Porichis et al., 2014). Cells were
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analyzed with a BD AriaII flow cytometer. Data were analyzed using FlowJo v887software (Tree Star).
Two technical and two biological replicates were obtained across all conditions using the two differ-
ent peptides at two different concentrations to stimulate naı¨ve CD4+ T cells.
Sequencing
Prior to sequencing, CD4+ T cells were separated from the co-cultured cells using Miltenyi MACS
negative selection as described above for the initial culturing. ChIP-sequencing for H3K4me2 and
H3K27Ac in the 1 mM peptide treatments was performed as described (Gilfillan et al., 2012), with
the following modifications: sodium butyrate was used to inhibit de-acetylation; and three RIPA and
three LiCl washes were performed instead of five and one. ChIP-sequencing for H3K4me2 and
H3K27Ac across the five conditions was performed as described (Gosselin et al., 2014). RNA-
sequencing was performed as described, with minor modifications (Wang et al., 2011). Two repli-
cates of the H3K4me2 ChIP-seq across all five conditions were obtained; three replicates across
three conditions and one across all five conditions were obtained for the H3K27Ac ChIP-seq; and
two replicates across all five conditions of the RNA-seq were obtained.
ChIP-sequencing antibodies used were: H3K4me2 (Millipore, cat. no. 07–030) and H3K27Ac
(Abcam, cat. no. ab4729 and Active Motif, cat. no. 39135).
To analyze the transcriptome of activated CD4+ T cells, we sorted CD69 positive cells. CD11c+
and CD4+ T cells were cultured for 22 hr as described above using two peptides at different concen-
trations K99A (10 mM and 100 mM) and PCC (0.1 mM and 10 mM). After harvesting, cells were stained
with Zombie Aqua live/dead stain (Biolegend) and with CD4-PE (clone RM4-5, eBioscience) and
CD69-PE Cy7 (clone H1.2F3, eBioscience) conjugated antibodies. Cells were sorted with a BD AriaII
cell sorter using a 70 mm nozzle. Live CD4+ cells were sorted into two populations according to the
expression of the CD69 activation marker. CD69+ cells from the various culture conditions were
used for RNA extraction. Unstimulated CD69- cells were used as controls. After extraction with Tri-
zol, RNA was PolyA-selected (MicroPoly(A) Purist kit, Ambion) and libraries were generated as previ-
ously described (Heinz et al., 2013). Samples were sequenced using NextSeq2 (Illumina) according
to manufacturer recommended protocols.
MEK inhibitor treatment
CD4+ T cells, isolated as described above, were pre-treated with 0.5 mM Promega U0126 (cat. no.
V1121) for thirty minutes at 37˚C. CD11c+ cells and peptides were subsequently as indicated and
cultured in the presence of the inhibitor for 24 hr.
Analysis
ChIP-sequencing reads were mapped to the mm10 genome using Bowtie2 (Langmead and Salz-
berg, 2012), and RNA-sequencing reads were mapped using STAR (Dobin et al., 2013). Default
allowed error rates were used, and only uniquely mapping reads were used in downstream analysis.
Initial processing of aligned data and peak calling was performed using Homer (Heinz et al., 2010).
IDR analysis (Landt et al., 2012) for ChIP-sequencing replicates was performed using the homer-idr
package (Allison, 2015). Vespucci (Allison et al., 2014) was used for counting AP-1 tags in gene
regions.
Gene Ontology analysis was performed using the Metascape Gene Annotation and Analysis
Resource tool (http://metascape.org/gp/index.html#/main/step1) using the express analysis settings
(Tripathi et al., 2015).
Super-enhancers were called using Homer (Heinz et al., 2010), which follows the published pro-
cedure (Hnisz et al., 2013; Love´n et al., 2013; Whyte et al., 2013) by first stitching together peaks
into larger regions and then sorting regions by normalized H3K27Ac tag count. Region scores are
plotted against rank, and a threshold is defined by finding the point at which the tangent to the plot-
ted rank-scores is one. Regions past that threshold are called super-enhancers.
Underlying data sets, including RPKM values and peaks, as well as code for all analyses described
is publicly available at https://github.com/karmel/and-tcr-affinity. Analyses were performed using
iPython Notebook (Perez and IPython, 2007). Clustering and PCA was performed using the scikit-
learn package (Pedregosa, 2011). For full execution details and parameters, please see the code in
the Github repository linked here.
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Activation signature scores
To generate the list of genes used in the activation signature score, we separately ran Principal Com-
ponent Analysis on two replicates of RNA-Seq data and also the combined expression data from
both replicates. Genes with an RPKM less than 100 in the No Peptide condition or a standard devia-
tion greater than 20% of the No Peptide expression level across replicates were then omitted from
the target set of genes. Remaining genes were sorted along PC1, and genes that were in the top
ten percent in all three data sets (215) or the bottom ten percent in all three data sets (137) were
included in the set of activation signature score genes used in analysis.
To compute the activation signature score, we take the dot product of the values of genes along
PC1 in the combined RNA-Seq data set and the mean-centered expression levels for those genes
for each sample in an experimental data set, yielding a single scalar score for each experiment. The
scores across samples are then scaled by the max score, ensuring values are in the range of [-1, 1].
The activation signature score tool is described and downloadable here: https://github.com/kar-
mel/and-tcr-affinity/tree/master/andtcr/rna/activationscore.
Public data
Publicly available datasets used for the analyses in Figure 3 and Figure 3—figure supplement 3 is
available from GEO with the following Accession Codes: GSE14308, GSE32224, GSE41866,
GSE42276, GSE54938, and GSE60337. AP-1 binding data is from GSE39756. For Figure 5E, the fol-
lowing datasets were used: GSE56456, GSE31233, GSE40463, GSE21365, GSE56098, GSE21512.
Accession codes
Raw and processed data are provided in the Gene Expression Omnibus (GEO) under accession num-
ber GSE69545.
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